Last reviewed · How we verify
Trial Assessing the Inhibitor of Programmed Cell Death Ligand 1 (PD-L1) Immune Checkpoint Atezolizumab (ATEZOLACC)
The primary objective of this randomized phase II trial is to evaluate the clinical benefits of the addition of atezolizumab to standard chemoradiotherapy (CRT) (first given concurrently with CRT, then continued as adjuvant treatment), compared with CRT alone, on investigator-assessed progression-free survival (PFS), as per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1).
Details
| Lead sponsor | Gustave Roussy, Cancer Campus, Grand Paris |
|---|---|
| Phase | PHASE2 |
| Status | COMPLETED |
| Enrolment | 189 |
| Start date | Mon Aug 13 2018 00:00:00 GMT+0000 (Coordinated Universal Time) |
| Completion | Tue May 13 2025 00:00:00 GMT+0000 (Coordinated Universal Time) |
Conditions
- Locally Advanced Cervical Cancer
Interventions
- Atezolizumab
- Radiotherapy
- Cisplatin
Countries
France